Gilead Sciences, Inc. Q2 2008 Earnings Call Transcript Gilead Sciences, Inc.(GILD) Q2 FY08 Earnings Call Executives Susan Hubbard - IR John F.
Milligan, PhD - President and COO Robin L.
Washington - Sr.
VP and CFO Kevin Young - EVP, Commercial Operations Norbert W.
Bischofberger, PhD ...
42nd International Childrens Games @ Kezar Stadium Topic - Topic - Loan Online Cigarettes Medical tests Top casino Free Ringtones Medicine news Building materials Cases Intimate goods Bracelets Cheap drugs online shop Ear rings Suits Cars Rolex Replica Cheap pharmacy shop ables Autos...
Drug delivery development news in brief 30-Jun-2008 - in-PharmaTechnologist's round-up of developments in the field of drug delivery, this week includes: a developmental micro-needle approach for ocular medications; AlphaRx' anti-infective Zysolin nanoparticles; and OptiNose's...
CORRECTION: Gentamicin increases risk of acute renal failure in cystic fibrosis patients In the fifth paragraph, the phrase 'at the time of acute renal failure or in the preceding week' has been replaced with 'in the preceding year'.] NEW YORK (Reuters Health) - The use of intravenous aminoglycosides, especially gentamicin,...
Axentis Pharma Gains Patents from BioDevelops Pharma to Further Cystic Fibrosis Program Axentis Pharmahas obtained patents from BioDevelops Pharma related to a cystic fibrosis treatment.The acquired therapeutic approach enables proteins, which get destroyed in spite of have some functionality, to escape.
In cystic fibrosis...
Axentis Pharma Gains Patents from BioDevelops Pharma to Further Cystic Fibrosis Program Axentis Pharmahas obtained patents from BioDevelops Pharma related to a cystic fibrosis treatment.The acquired therapeutic approach enables proteins, which get destroyed in spite of have some functionality, to escape.
In cystic fibrosis...
Zysolin(TM) Improves Survival in Pivotal Animal Studies MARKHAM, ON, June 26 /PRNewswire-FirstCall/ - AlphaRx is pleased to report additional pre-clinical data on Zysolin(TM), an inhaled Tobramycin nanoparticles intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in...
AlphaRx's pneumonia drug improves survival in preclinical studies Injectible Tobramycin is used in the initial empirical therapy for mechanically-ventilated patients (VAP) and is also well known for its nephrotoxicity.AlphaRx's Zysolin is intended to replace injectible Tobramycin in VAP...
AlphaRx's pneumonia drug improves survival in preclinical studies AlphaRx has reported additional pre-clinical data on Zysolin, an inhaled Tobramycin nanoparticle intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in intubated and mechanically-ventilated patients.Injectible ...
Learn about the World Ophthalmic Pharmaceutical Drugs Market - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ Million.
Learn about the World Ophthalmic Pharmaceutical Drugs Market LONDON, UNITED KINGDOM -- (MARKET WIRE) -- 06/27/08 -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.This report analyzes the worldwide markets...
Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technolog ZURICH, Switzerland, June 26 /PRNewswire/ -- The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.The company has acquired the...
Axentis Pharma Gains Patents from BioDevelops Pharma to Further Cystic Fibrosis Program Axentis Pharmahas obtained patents from BioDevelops Pharma related to a cystic fibrosis treatment.The acquired therapeutic approach enables proteins, which get destroyed in spite of have some functionality, to escape.
In cystic fibrosis...
Zysolin Improves Survival in Pivotal Animal Studies AlphaRx's inhaled Tobramycin nanoparticles demonstrated superior therapeutic efficacy in mouse models of acute Pseudomonas aeruginosa pneumonia.Zysolin(TM) could be a first-in-class anti-infective nanomedicine MARKHAM, ON, June 26,...
Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technolog ZURICH, Switzerland, June 26 /PRNewswire/ -- The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.The company has acquired the...
Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technolog ZURICH, Switzerland, June 26 /PRNewswire/ -- The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.The company has acquired the...
Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technolog ZURICH, Switzerland, June 26 /PRNewswire/ -- The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.The company has acquired the...
Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technolog ZURICH, Switzerland, June 26 /PRNewswire/ -- The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.The company has acquired the...
Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis Medical Patent News The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.The company has acquired the rights from an Austrian firm...
China Sky One Medical, Inc. Obtains SFDA Approval to Produce Four New Drugs HARBIN, China, June 18 Xinhua-PRNewswire-FirstCall China Sky One Medical, Inc.(Amex: CSY) (''China Sky One'' or ''the Company''), a China-based manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic kit...
China Sky One receives SFDA approval to produce 4 drugs China Sky One Medical, Inc., a China-based manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic kit products, has obtained approval from the State Food and Drug Administration (SFDA) in China for four new drugs-...
Gentamicin increases risk of acute renal failure in cystic fibrosis patients NEW YORK (Reuters Health) - The use of intravenous aminoglycosides, especially gentamicin, increases the risk of acute renal failure in patients with cystic fibrosis (CF), according to a report in the June issue of Thorax.'Don't use...
China Sky One Medical wins approval to produce four new drugs China Sky One Medical has obtained approval from the State Food and Drug Administration in the People's Republic of China for four new drugs, Tobramycin eye drops, compound Zinc Sulfate eye drops, Ofloxacin suppositories and Ofloxacin...
China Sky One Medical, Inc. Obtains SFDA Approval to Produce Four New Drugs /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc.(''China Sky One'' or ''the Company''), a China-based manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic kit products, announced today that it has...
CSY: Obtains Approval for 4 New Drugs Ridgeland, MS, JUN 18, 2008 (EventX/Knobias.com via COMTEX News Network) -- By Jay Everitt, jeveritt@knobias.com China Sky One Medical, Inc.(CSY) announced that it has obtained approval from the State Food and Drug Administration (SFDA)...
